Comments for asia healthspace

Comment on Wake up call for the Lancet? or Wake up call to India and world? by Damjan Denoble

Damjan Denoble — Sat, 04 Sep 2010 21:09:19 +0000

Great post Tej. I’ll have you know though that we do not share an alma mater. He simply worked there. BIG difference. What a disgrace he is though….

Further thoughts at my place.

Comment on Healthcare country profile: Hong Kong by Nonoy Oplas

Nonoy Oplas — Wed, 01 Sep 2010 17:38:30 +0000

Thank you for this article. I used it in my blog entry, “Healthcare competition 4: Hong Kong”, http://funwithgovernment.blogspot.com/2010/09/healthcare-competition-4-hong-kong.html.

Comment on Healthcare country profile: Singapore by Nonoy Oplas

Nonoy Oplas — Sun, 29 Aug 2010 13:07:14 +0000

Thanks for this reprint. I made a blog entry on Singapore’s healthcare at http://funwithgovernment.blogspot.com/2010/08/healthcare-competition-3-singapore.html

I have also written an earlier short discussion on healthcare in Switzerland and Canada in the same blog.

Comment on Medicine, media and accountability: What’s the hazard ratio of that? by asia healthspace » Blog Archive » Wake up call for the Lancet? or Wake up call to India?

Tue, 24 Aug 2010 07:39:55 +0000

[...] Part of your view appears to me to be a tad naive Damjan. The Lancet it seems would be well-advised to review their quality control processes. A supposed Rhodes Scholar? A Duke researcher? Isn’t that your Alma Mater Damjan (kidding of course)? 12 years for the Wilkinson retraction? The Wilkinson retraction was regarding the issue of autism being linked to MMR vaccine which turned out to be b-ll sh-t (please read Medicine, media and accountability: What’s the hazard ratio of that?). [...]

Comment on Little red riding hood (society) and the big bad wolf (branded pharma) by Nonoy Oplas

Nonoy Oplas — Wed, 11 Aug 2010 01:55:07 +0000

Good points, Dr. Tej. People are getting more demanding in healthcare. If they are sick, they want to get well within 1 or 2 days, not 1 or 2 weeks. Hence, they demand more powerful, more revolutionary drugs and treatment. But health collectivism and coercion force pharma companies and retailers to focus on low price. If the price is deemed “expensive” even if the drugs are effective and powerful, governments come in to impose price control and similar schemes.

The drug price control policy in the Philippines will turn one year old this coming August 15. The policy is a failure in improving the poor’s access to more powerful drugs. What it succeeded is giving the rich and middle class lots of savings through the mandatory 50 percent price cut of branded drugs. The policy also succeeded in drawing many middle class patients back to supporting branded drugs and moving away from generics, despite the government’s 20+ yrs old promotion of generics.